Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Tampilan
• 07/18/23
0
0
Menanamkan
administrator
Pelanggan
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru